• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS EX filed by Abpro Holdings Inc

    4/23/25 4:16:11 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    POS EX 1 ea0238814-posex_abprohold.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

    As filed with the Securities and Exchange Commission on April 23, 2025

    Registration No. 333-284021

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-1

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

     

    Abpro Holdings, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   2834   87-1013956

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification No.)

     

    68 Cummings Park Drive

    Woburn, Massachusetts 01801

    1-800 -396-5890

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Miles Suk

    Chief Executive Officer

    Abpro Holdings, Inc.

    68 Cummings Park Drive

    Woburn, Massachusetts 01801

    1-800 -396-5890

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Jonathan H. Talcott

    E. Peter Strand

    Michael K. Bradshaw, Jr.

    Nelson Mullins Riley & Scarborough LLP

    101 Constitution Avenue, NW, Suite 900

    Washington, D.C. 20001

    (202) 689-2800

     

     

     

    Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

     

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☒ (333-284021)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    This Post-Effective Amendment No. 1 to the Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-1 of Abpro Holdings, Inc. (File No. 333-284021), initially filed on December 23, 2024, and declared effective by the SEC on February 12, 2025 (the “Registration Statement”), is being filed as an exhibit-only filing solely to file a consent of Wolf & Company, P.C. with respect to its report dated April 15, 2025, related to the financial statements of Abpro Holdings, Inc. contained in the Annual Report on Form 10-K of Abpro Holdings, Inc. for the year ended December 31, 2024 and included in the Prospectus Supplement No. 1 dated April 23, 2025 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the “Consent”). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement, and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

     

     

     

     

    PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    Exhibit

    Number

      Description
    23.1*   Consent of Wolf & Company, P.C.

     

    *Filed herewith.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Massachusetts, on the 23rd day of April 2025.

     

      ABPRO HOLDINGS, INC.
         
      By: /s/ Miles Suk
        Miles Suk
        Chief Executive Officer and Chairman of the Board

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Miles Suk, the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments, including post-effective amendments to the Registration Statement, including a prospectus or an amended prospectus therein and any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462 under the Securities Act, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact as agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Name   Position   Date
             
    /s/ Miles Suk   Chief Executive Officer and Chairman of the Board   April 23, 2025
    Miles Suk (Principal Executive Officer, Principal Financial and Accounting Officer)  
             
    /s/ Anthony D. Eisenberg   Director   April 23, 2025
    Anthony D. Eisenberg    
             
    /s/ Soo Young Lee   Director   April 23, 2025
    Soo Young Lee    
             
    /s/ Ian McDonald   Director   April 23, 2025
    Ian McDonald    

     

     

    II-2

     

     

    Get the next $ABP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    SEC Filings

    View All

    Abpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - Abpro Holdings, Inc. (0001893219) (Filer)

    2/11/26 4:15:54 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Abpro Holdings Inc

    SCHEDULE 13G - Abpro Holdings, Inc. (0001893219) (Subject)

    2/9/26 4:07:42 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Holdings Inc filed SEC Form 8-K: Leadership Update

    8-K - Abpro Holdings, Inc. (0001893219) (Filer)

    2/3/26 4:15:45 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lee Soo Young

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/7/25 9:08:24 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Eisenberg Anthony D.

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    7/29/25 9:23:12 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

    FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the

    1/6/26 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

     IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP, "Abpro")), a biotechnology company developing novel breakthrough therapeutics for solid tumors, together with its co-development partner Celltrion, Inc., today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA

    12/15/25 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

    BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements. "We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum," said Miles Suk, Chief Executive Officer and Chairman of Abpro. "We've taken decisive steps to position the Company for sustainable growth. With

    12/9/25 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/19/25 8:37:52 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/1/25 4:21:30 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Abpro Statement on the Departure of Former CEO Ian Chan

    WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

    3/10/25 6:34:55 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care